Undifferentiated Carcinoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Clinical Trials

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
Conditions:   Accelerated Phase of Disease;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Phase of Disease;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Recurrent DiseaseInterventions:   Drug: Tipifarnib;   Other: Laboratory Biomarker AnalysisSponsor:   National Cancer Institute (NCI)Active, not recruiting - verified August 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2014 Category: Research Source Type: clinical trials

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
Conditions:   Accelerated Phase of Disease;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Phase of Disease;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Recurrent DiseaseInterventions:   Other: Laboratory Biomarker Analysis;   Drug: TipifarnibSponsor:   National Cancer Institute (NCI)Active, not recruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2014 Category: Research Source Type: clinical trials

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
Conditions:   Accelerated Phase of Disease;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Phase of Disease;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Recurrent DiseaseInterventions:   Drug: Tipifarnib;   Other: Laboratory Biomarker AnalysisSponsor:   National Cancer Institute (NCI)Active, not recruiting - verified August 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2014 Category: Research Source Type: clinical trials

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
Conditions:   Accelerated Phase of Disease;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Phase of Disease;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Recurrent DiseaseInterventions:   Drug: Tipifarnib;   Other: Laboratory Biomarker AnalysisSponsor:   National Cancer Institute (NCI)Active, not recruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2014 Category: Research Source Type: clinical trials

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
Conditions:   Accelerated Phase of Disease;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Phase of Disease;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Recurrent DiseaseInterventions:   Drug: Tipifarnib;   Other: Laboratory Biomarker AnalysisSponsor:   National Cancer Institute (NCI)Active, not recruiting - verified August 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2014 Category: Research Source Type: clinical trials

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
Conditions:   Accelerated Phase of Disease;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Phase of Disease;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Recurrent DiseaseInterventions:   Other: Laboratory Biomarker Analysis;   Drug: TipifarnibSponsor:   National Cancer Institute (NCI)Active, not recruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2014 Category: Research Source Type: clinical trials

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
Conditions:   Accelerated Phase of Disease;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Phase of Disease;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Recurrent DiseaseInterventions:   Drug: Tipifarnib;   Other: Laboratory Biomarker AnalysisSponsor:   National Cancer Institute (NCI)Active, not recruiting - verified August 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2014 Category: Research Source Type: clinical trials

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
Conditions:   Accelerated Phase of Disease;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Phase of Disease;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Recurrent DiseaseInterventions:   Other: Laboratory Biomarker Analysis;   Drug: TipifarnibSponsor:   National Cancer Institute (NCI)Active, not recruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2014 Category: Research Source Type: clinical trials